AMRX - Amneal Pharmaceuticals Non-GAAP EPS of $0.18 misses by $0.02 revenue of $537M beats by $3.59M
Amneal Pharmaceuticals press release (NYSE:AMRX): Q4 Non-GAAP EPS of $0.18 misses by $0.02. Revenue of $537M (+5.3% Y/Y) beats by $3.59M. Provides 2022 Financial Guidance of $2.15 to $2.25 billion ($2.15B consensus) in net revenue and $540 to $560 million in adjusted EBITDA. Adjusted diluted EPS of $0.80-$0.85 vs. $0.90 consensus
For further details see:
Amneal Pharmaceuticals Non-GAAP EPS of $0.18 misses by $0.02, revenue of $537M beats by $3.59M